YCYi-Hsuan Chiang

Yi-Hsuan Chiang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Yi-Hsuan Chiang has a total of 21 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Metabolic Alterations in HSCs during Aging and Leukemogenesis

    by Yi-Hsuan Chiang, Stephan Emmrich, Nicola Vannini

    Aging is a multifaceted process associated with a functional decline in cellular function over time, affecting all lifeforms. During the aging process, metabolism, a fundamental hallmark of life ( 1 ), is profoundly altered. In the context of hematopoiesis, the proper function of hematopoietic stem cells, at the apex of the blood system, is tightly linked to their energy metabolism, which in turn shapes hematopoietic output. Here, we review the latest developments in our understanding of the metabolic states and changes in aged hematopoietic stem cells, molecular players and pathways involved in aged hematopoietic stem cell metabolism, the consequences of perturbed metabolism on clonal hematopoiesis and leukemogenesis, and pharmacologic/genetic strategies to reverse or rejuvenate altered metabolic phenotypes.


  • Open Access

    FIGURE 1 from Urolithin-A Promotes CD8+ T Cell–mediated Cancer Immunosurveillance via FOXO1 Activation

    by Pierpaolo Ginefra, Helen Carrasco Hope, Yi-Hsuan Chiang, Sophie Nutten, Stephanie Blum, George Coukos, Nicola Vannini

    UroA supplementation slows tumor progression in immunocompetent mice. A, Analysis of tumor growth rate of B16 tumors cells injected in immunocompetent C57/Bl6 mice fed for 4 weeks with UroA-enriched food before tumor cells injection. B, Analysis of tumor growth rate of B16 tumors cells injected in immunodeficient NSG mice fed with control or UroA-enriched diet for 4 weeks before tumor cells injection. C, Analysis of tumor growth rate of B16 tumors implanted in mice as in A and treated with or without anti-CD8 antibody. D, Schematic representation of in vivo feeding experiment followed by withdrawal condition. Mice were fed for 4 weeks with UroA-enriched or control food. Half of the mice were kept under the initial feeding condition, the other half received conventional food. One week after, B16 cells were subcutaneously injected. E, Analysis of tumor growth rate in H. F, Tumor growth rate of B16 tumors in mice as in A and treated with anti PD-1 therapy. Data are mean ± SEM. Each dot represents a biological replicate. In A, control = 6 mice, UroA = 7 mice. In B, control = 5 mice, UroA = 5 mice. In C, control = 6 mice, UroA = 7mice, control+CD8 = 6 mice, UroA+CD8 = 6 mice. In E, control and UroA = 7 mice, on/off condition = 5 mice. In F, each group has 6 mice. Data were analyzed by two-sided Student t test or by ANOVA test followed by multiple comparison test (**, P < 0.01). Representative results of two independent experiments.

  • Open Access

    Figure S1 from Urolithin-A Promotes CD8+ T Cell–mediated Cancer Immunosurveillance via FOXO1 Activation

    by Pierpaolo Ginefra, Helen Carrasco Hope, Yi-Hsuan Chiang, Sophie Nutten, Stephanie Blum, George Coukos, Nicola Vannini

    UroA supplementation does not modulate immune infiltrate composition

  • Open Access

    FIGURE 1 from Urolithin-A Promotes CD8+ T Cell–mediated Cancer Immunosurveillance via FOXO1 Activation

    by Pierpaolo Ginefra, Helen Carrasco Hope, Yi-Hsuan Chiang, Sophie Nutten, Stephanie Blum, George Coukos, Nicola Vannini

    UroA supplementation slows tumor progression in immunocompetent mice. A, Analysis of tumor growth rate of B16 tumors cells injected in immunocompetent C57/Bl6 mice fed for 4 weeks with UroA-enriched food before tumor cells injection. B, Analysis of tumor growth rate of B16 tumors cells injected in immunodeficient NSG mice fed with control or UroA-enriched diet for 4 weeks before tumor cells injection. C, Analysis of tumor growth rate of B16 tumors implanted in mice as in A and treated with or without anti-CD8 antibody. D, Schematic representation of in vivo feeding experiment followed by withdrawal condition. Mice were fed for 4 weeks with UroA-enriched or control food. Half of the mice were kept under the initial feeding condition, the other half received conventional food. One week after, B16 cells were subcutaneously injected. E, Analysis of tumor growth rate in H. F, Tumor growth rate of B16 tumors in mice as in A and treated with anti PD-1 therapy. Data are mean ± SEM. Each dot represents a biological replicate. In A, control = 6 mice, UroA = 7 mice. In B, control = 5 mice, UroA = 5 mice. In C, control = 6 mice, UroA = 7mice, control+CD8 = 6 mice, UroA+CD8 = 6 mice. In E, control and UroA = 7 mice, on/off condition = 5 mice. In F, each group has 6 mice. Data were analyzed by two-sided Student t test or by ANOVA test followed by multiple comparison test (**, P < 0.01). Representative results of two independent experiments.

  • Open Access

    FIGURE 3 from Urolithin-A Promotes CD8+ T Cell–mediated Cancer Immunosurveillance via FOXO1 Activation

    by Pierpaolo Ginefra, Helen Carrasco Hope, Yi-Hsuan Chiang, Sophie Nutten, Stephanie Blum, George Coukos, Nicola Vannini

    UroA induces FOXO1 transcriptional activity in CD8+ T cell. A, Quantification of FOXO1 target genes in CD8+ T cells culture with 5 µmol/L UroA in IL15/7 condition in vitro. Values are expressed as fold change compare with control condition. B, Analysis of FOXO1 target genes expression levels in CD8+ T cells isolated from mice fed with control or UroA-enriched food for 4 weeks. Values are expressed as fold change compare with control condition. C, FOXO1 phosphorylation in CD8+ T cells treated for 24 hours with 5 µmol/L UroA in vitro. D, FOXO1 phosphorylation in CD8+ T isolated from mice fed with control or UroA diet. E, Representative confocal images of CD8+ T cells stained with FOXO1 (green) CD8 (red), and DAPI (blue) under the indicated culture condition (scale bar, 5 µm) in vitro (UroA = 5 µmol/L). The LUT images represent FOXO1 intensity staining (left). Quantification of nuclear FOXO1 in control and UroA (5 µmol/L) treated CD8+ T cells) in vitro (right). F, Akt S473 phosphorylation in CD8+ T cells treated for 24 hours with 5 µmol/L UroA in vitro and then stimulated with CD3/CD28 antibodies for 30 minutes (Act condition). Data are mean ± SEM. Each dot represents a biological replicate. In A, sample size n = 6. In B, sample size n = 5. In C, sample size n = 8. In D, sample size n = 5. In E, control = 72, UroA = 68. In F, sample size n = 4. Data were analyzed by two-sided Student t test (*, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001). Representative results of at least two independent experiments or two pooled experiments.

  • Open Access

    FIGURE 2 from Urolithin-A Promotes CD8+ T Cell–mediated Cancer Immunosurveillance via FOXO1 Activation

    by Pierpaolo Ginefra, Helen Carrasco Hope, Yi-Hsuan Chiang, Sophie Nutten, Stephanie Blum, George Coukos, Nicola Vannini

    UroA promotes naïve T-cell expansion in vivo and memory formation in vitro.A, Schematic representation of in vivo feeding experiment. B, Frequency of naïve CD8+ T cells (CD62L+CD44−) isolated from the spleen of mice fed with control or UroA-enriched diet. C, Expression level of CD62 L in CD8+ T cells from B, values are normalized to the control. D, Frequency of central memory (CD62L+CD44+) in CD8+ T cells treated for 4 days with 5 µmol/L UroA in IL15/7 condition in vitro. E, Expression level of central memory marker CD62 L in C. F, Analysis of tumor growth rate of B16-Ova tumor-bearing mice adoptively transferred with no cells (saline = 13 mice), control OT-1 CD8+ T cells (control = 10 mice) and UroA-treated OT-1 CD8+ T cells (UroA = 13 mice). G, Quantification of expression level of TIM-3 and PD-1 in TILs from F measured (control = 7, UroA = 6). H, Frequency of terminally exhausted T cells (TCF1−PD1+TIM3+) from G. Data are mean ± SEM. Each dot represents a biological replicate. In B and C, control n = 10 mice, UroA = 12 mice. In D and E, sample size n = 5. Data were analyzed by two-sided Student t test (*, P < 0.05; **, P < 0.01). Representative results of two independent experiments or two pooled experiments.

  • Open Access

    FIGURE 4 from Urolithin-A Promotes CD8+ T Cell–mediated Cancer Immunosurveillance via FOXO1 Activation

    by Pierpaolo Ginefra, Helen Carrasco Hope, Yi-Hsuan Chiang, Sophie Nutten, Stephanie Blum, George Coukos, Nicola Vannini

    UroA-induced FOXO1 transcriptional activity is mitophagy independent. A, Quantification of CD62 L expression level in CD8+ T treated with UroA (5 µmol/L) and in presence of FOXO1 inhibitor (Foxo inh 50 nmol/L) for 48 hours in vitro. Values are expressed as fold change compare with control condition. B, Schematic representation of FOXO1 inhibition in vivo analyzed in C. C, Quantification of naïve CD8+ T population isolated from mice fed with UroA diet and treated with Foxo inh. Values are expressed as fold change compare with control condition (left). Quantification of CD62 L expression level in CD8+ T isolated from mice fed with UroA diet and treated with Foxo inh (right) for 48 hours in vitro. D, Expression level of PGC1α in CD8+ T treated with UroA (5 µmol/L) for 48 hours in vitro. E, Quantification of Mito-QC CD8+ T cells engaging mitophagy under indicated condition in vitro for 24 hours (UroA 5 µmol/L, Foxo inh 50 nmol/L). Quantification of mCherry/GFP ratio from E (right). F, Expression level of PGC1α in CD8+ T cells cultured in presence of Foxo inh (50 nmol/L) or mitophagy blocker (mDivi 10 µmol/L) for 48 hours in vitro. Data are mean ± SEM. Each dot represents a biological replicate. In A, sample size n = 9. In C, sample size n = 8. In D, sample size n = 6. In E, sample size n = 7. In F, sample size n = 3. Data were analyzed by two-sided Student t or ANOVA test followed by multiple comparison test (*, P < 0.05; **, P < 0.01; ****, P < 0.0001). Representative results of at least two independent experiments or two pooled experiments.

  • Open Access

    Figure S1 from Urolithin-A Promotes CD8+ T Cell–mediated Cancer Immunosurveillance via FOXO1 Activation

    by Pierpaolo Ginefra, Helen Carrasco Hope, Yi-Hsuan Chiang, Sophie Nutten, Stephanie Blum, George Coukos, Nicola Vannini

    UroA supplementation does not modulate immune infiltrate composition

  • Open Access

    Figure S3 from Urolithin-A Promotes CD8+ T Cell–mediated Cancer Immunosurveillance via FOXO1 Activation

    by Pierpaolo Ginefra, Helen Carrasco Hope, Yi-Hsuan Chiang, Sophie Nutten, Stephanie Blum, George Coukos, Nicola Vannini

    UroA modulates FOXO1 target genes expression but not FOXO1 expression in vitro

  • Open Access

    Data from Urolithin-A Promotes CD8+ T Cell–mediated Cancer Immunosurveillance via FOXO1 Activation

    by Pierpaolo Ginefra, Helen Carrasco Hope, Yi-Hsuan Chiang, Sophie Nutten, Stephanie Blum, George Coukos, Nicola Vannini

    Naïve T cells are key players in cancer immunosurveillance, even though their function declines during tumor progression. Thus, interventions capable of sustaining the quality and function of naïve T cells are needed to improve cancer immunoprevention.In this context, we studied the capacity of Urolithin-A (UroA), a potent mitophagy inducer, to enhance T cell–mediated cancer immunosurveillance.We discovered that UroA improved the cancer immune response by activating the transcription factor FOXO1 in CD8+ T cell. Sustained FOXO1 activation promoted the expression of the adhesion molecule L-selectin (CD62L) resulting in the expansion of the naïve T cells population. We found that UroA reduces FOXO1 phosphorylation favoring its nuclear localization and transcriptional activity. Overall, our findings determine FOXO1 as a novel molecular target of UroA in CD8+ T cells and indicate UroA as promising immunomodulator to improve cancer immunosurveillance.Significance:Urolithin-A, a potent mitophagy inducer, emerges as a promising tool to enhance cancer immunosurveillance by activating the FOXO1 transcription factor in CD8+ T cells. This activation promotes the expansion of naïve T cells, offering a novel avenue for improving cancer immune response and highlighting UroA as a potential immunomodulator for bolstering our body's defenses against cancer.